Janus Biotherapeutics, a Massachusetts-based autoimmunity therapeutics company, is collaborating with Roche on the development of a small molecule toll-like receptor (TLR) inhibitor with the potential to address several autoimmune diseases. TLRs are class of proteins in the innate immune system. Evidence links aberrant TLR activation and signaling with the development of autoimmune disorders. Janus will work exclusively with Roche on TLR R&D.

“Even if still in a preclinical phase, Janus’ unique triple TLR antagonist has potential therapeutic applications across multiple autoimmune diseases with high unmet medical need,” said Grayson Lipford, Janus’ co-founder and chief scientific officer. “The Janus program will be a part of Roche’s external drug discovery portfolio and benefit from Roche’s know-how in drug development and translational medicine and strong heritage in autoimmune diseases.”

Janus will receive an upfront cash payment and R&D funding over a collaboration period. Following the achievement of certain predetermined milestones, Roche will have the option to acquire Janus.